Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Abuses: Congressional Panel’s Focus Turns To Federal Trade Commission

Executive Summary

During bipartisan, but one-sided, hearing about US FDA’s limited authority to ensure generic drug makers can access restricted distribution reference products for bioequivalence testing, one lawmaker wants to know what FTC is doing about the issue.


Related Content

Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
FDA User Fee Bills: Is It Possible For Reauthorization To Be Too Clean?
Generic Drug Puzzle: Why Did ANDA Submissions Spike Again?
The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
REMS “Abuses” Concern FDA, But Can Scolding Help Speed Generic Entry?
Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters
FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts